When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Hiperplasia adrenal congênita

Última revisão: 16 Jan 2025
Última atualização: 11 Dec 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • perda de peso
  • retardo do crescimento pôndero-estatural
  • vômitos
  • hipotensão
  • genitália atípica
  • hiperpigmentação
Detalhes completos

Outros fatores diagnósticos

  • baixa estatura
  • puberdade precoce
  • menstruação irregular
  • infertilidade
  • calvície de padrão masculino (mulheres)
  • ovários policísticos
  • hirsutismo
  • acne
Detalhes completos

Fatores de risco

  • predisposição genética
Detalhes completos

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • 17-hidroxiprogesterona (17-OHP) sérica
  • teste de estímulo com o hormônio adrenocorticotrófico (ACTH)
  • cortisol sérico
  • bioquímica sérica
  • análise genética
  • cariótipo ou hibridização fluorescente in situ (FISH) para detecção dos cromossomos X e Y
Detalhes completos

Investigações a serem consideradas

  • medição de esteroides adicionais
  • mensuração da renina plasmática/atividade da renina plasmática
  • ultrassonografia adrenal e pélvica
Detalhes completos

Algoritmo de tratamento

AGUDA

durante cirurgia, afecção febril ou outros estresses

CONTÍNUA

HAC na forma clássica

forma não clássica

Colaboradores

Autores

Maria Vogiatzi, MD

Professor of Pediatrics

Division of Endocrinology and Diabetes

Children’s Hospital of Philadelphia

Philadelphia

PA

Declarações

MV is a consultant for Spruce Bioscience, Crinetics and Eton Pharmaceuticals and receives research support from Neurocrine Bioscience, Spruce Bioscience, Adrenas Therapeutics and Crinetics Pharmaceuticals lnc.

Marissa J Kilberg, MD, MSEd

Assistant Professor of Pediatrics

Division of Endocrinology and Diabetes

Children’s Hospital of Philadelphia

Philadelphia

PA

Declarações

MK has received consulting fees from Verily, Inc. related to type 1 diabetes. MK receives salary and travel support from the Cystic Fibrosis Foundation as part of the EnVisionIII cohort. MK participates in industry sponsored research but is not the direct recipient of these grants and receives no salary support or travel support from this.

Agradecimentos

The contributors would like to gratefully acknowledge Dr Mabel Yau, Dr Ahmed Kattab, Dr Saroj Nimkarn, Dr Karen Lin-Su, Dr Oksana Lekarev, Dr Maria New, Dr Jessica Kaltman and Dr Adnan Qamar, previous contributors to this topic. MY, AK, SN, JK and AQ declare that they no competing interests. KLS is medical director of the CARES Foundation and an author of several references cited in this topic. OL is on the Medical Advisory Board of the CARES Foundation. MN is an author of several references cited in this topic.

Revisores

Richard Auchus, MD, PhD

Professor of Internal Medicine

Division of Metabolism, Endocrinology and Diabetes

University of Michigan

Ann Arbor

MI

Declarações

RA contributed to the Endocrine Society CPG on CAH and has been on the board of directors for the past 3 years. He has conducted CAH-related contracted clinical trials and has consulted for Janssen Pharmaceuticals, Millendo Therapeutics, Spruce Biosciences, Neurocrine Biosciences, and Diurnal Ltd.

  • Hiperplasia adrenal congênita images
  • Diagnósticos diferenciais

    • hipoplasia adrenal congênita (HAC) ligada ao cromossomo X
    • Causas genéticas da insuficiência adrenal primária
    • Doença de Addison
    Mais Diagnósticos diferenciais
  • Diretrizes

    • Guidelines on paediatric urology
    • Best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency
    Mais Diretrizes
  • padlock-lockedConectar-se ou assinar para acessar todo o BMJ Best Practice

O uso deste conteúdo está sujeito ao nosso aviso legal